Academic Journal
Comparison of Humoral Antibody Responses and Seroconversion Rates between Two Homologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination in Patients Undergoing Maintenance Hemodialysis
العنوان: | Comparison of Humoral Antibody Responses and Seroconversion Rates between Two Homologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination in Patients Undergoing Maintenance Hemodialysis |
---|---|
المؤلفون: | Shih-Hsin Hsiao, Yuh-Mou Sue, Chih-Chin Kao, Hui-Wen Chang, Yen-Chung Lin, Ching-Sheng Hung, Yi-Chen Hsieh, Shiao-Ya Hong, Chi-Li Chung, Jer-Hwa Chang, Ying-Shih Su, Ming-Che Liu, Kevin Shu-Leung Lai, Ko-Ling Chien, Jude Chu-Chun Wang, Chung-Yi Cheng, Te-Chao Fang |
المصدر: | Vaccines, Vol 11, Iss 7, p 1161 (2023) |
بيانات النشر: | MDPI AG, 2023. |
سنة النشر: | 2023 |
المجموعة: | LCC:Medicine |
مصطلحات موضوعية: | hemodialysis, COVID, vaccine response, Medicine |
الوصف: | Background: Hemodialysis patients are at an increased risk of SARS-CoV-2 infection and are excluded from preauthorization COVID-19 vaccine trials; therefore, their immunogenicity is uncertain. Methods: To compare the antibody responses to homologous ChAdOx1 and mRNA-1273 SARS-CoV-2 vaccination in hemodialysis patients, 103 age- and sex-matched hemodialysis patients with two homologous prime-boost vaccinations were recruited to detect anti-receptor-binding domain (RBD) IgG levels and seroconversion rates (SCRs) 14 days after a prime dose (PD14), before and 28 days after a boost dose (pre-BD0 and BD28). Results: Both mRNA-1273 and ChAdOx1 vaccinations elicited immunogenicity in study subjects, and the former induced higher anti-RBD IgG levels than the latter. The SCRs of both groups increased over time and varied widely from 1.82% to 97.92%, and were significantly different at PD14 and pre-BD0 regardless of different thresholds. At BD28, the SCRs of the ChAdOx1 group and the mRNA-1273 group were comparable using a threshold ≥ 7.1 BAU/mL (93.96% vs. 97.92%) and a threshold ≥ 17 BAU/mL (92.73% vs. 97.92%), respectively, but they were significantly different using a threshold ≥ 20.2% of convalescent serum anti-RBD levels (52.73% vs. 95.83%). The seroconversion (≥20.2% of convalescent level) at BD28 was associated with mRNA-1273 vaccination after being adjusted for age, sex, body mass index, and the presence of solicited reactogenicity after a prime vaccination. Conclusion: Our prospective, observational cohort indicates that a full prime-boost mRNA-1273 vaccination is likely to provide higher immune protection in hemodialysis patients compared to ChAdOx1, and this population with a prime-boost ChAdOx1 vaccination should be prioritized for a third dose. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2076-393X |
Relation: | https://www.mdpi.com/2076-393X/11/7/1161; https://doaj.org/toc/2076-393X |
DOI: | 10.3390/vaccines11071161 |
URL الوصول: | https://doaj.org/article/8b2eb08ccf0d47cf8f3adb3f14a378ae |
رقم الانضمام: | edsdoj.8b2eb08ccf0d47cf8f3adb3f14a378ae |
قاعدة البيانات: | Directory of Open Access Journals |
كن أول من يترك تعليقا!